成人B站猎奇版

Gastric cancer incidence was lower after adjusting for certain factors in post hoc analyses

Despite problematic dataset, risk/benefit profile not favorable with PD-L1 expression below 1

26% of patients receiving tulisokibart achieved clinical remission vs 1% with placebo

Data since approvals suggest benefits limited to subgroups with PD-L1 expression of at least 1%

Drugmaker none-too-pleased with agency's request for additional studies

Agency advisors put their foot down on shaky science for Ocaliva in primary biliary cholangitis

In trials, guselkumab more than doubled remission rates versus placebo

Agency advisory panel to examine complicated efficacy data and liver safety concerns

Botox can help "no-burp syndrome" symptoms

Mucosal damage seen on upper endoscopy associated with 76% higher Parkinson's risk

No difference in overall survival with versus without bolus, less toxicity without

Having a medical condition was tied to increased risk of suicide in a dose-response-like manner

It's time to look at oral vaccines to prevent C. difficile infections, experts say

IOC data show "about a 10% infection rate in those who swam in the Seine"